Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference, 4th edition, 372 pages + the daily Top 10

Lung Cancer

Free Subscription 08.06.2020 1 Am J Clin Oncol 1 Ann Thorac Surg 7 Anticancer Res 1 BMC Cancer 1 Cancer Cell 1 Cancer Epidemiol Biomarkers Prev 2 Cancer Sci 2 Clin Cancer Res 1 Clin Lung Cancer 1 Eur Respir J 2 Int J Cancer 1 Int J Radiat Oncol Biol Phys 3 J Cancer Res Clin Oncol 1 J Surg Oncol 3 J Thorac Oncol 3 JAMA Oncol 1 Lancet Gastroenterol Hepatol 2 Lancet Respir Med 2 Lung Cancer 1 N Engl J Med 2 Nat Med 1 Oncol Rep 1 Oncologist 3 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Clin Oncol

1. YUSUF D, Walton RN, Hurry M, Farrer C, et al
   Population-based Treatment Patterns and Outcomes for Stage III Non-Small Cell Lung Cancer Patients: A Real-world Evidence Study.
   Am J Clin Oncol. 2020 May 29. doi: 10.1097/COC.0000000000000716.
   PubMed         Abstract available
   
   

   
   Ann Thorac Surg

2. WILSHIRE CL, Rayburn JR, Chang SC, Gilbert CR, et al
   Not following the rules in guideline care for lung cancer diagnosis and staging has negative impact.
   Ann Thorac Surg. 2020 May 31. pii: S0003-4975(20)30782.
   PubMed         Abstract available
   
   

   
   Anticancer Res

3. SP N, Kang DY, Kim DH, Yoo JS, et al
   Tannic Acid Inhibits Non-small Cell Lung Cancer (NSCLC) Stemness by Inducing G0/G1 Cell Cycle Arrest and Intrinsic Apoptosis.
   Anticancer Res. 2020;40:3209-3220.
   PubMed         Abstract available
   
   
4. TAKAHASHI K, Menju T, Nishikawa S, Miyata R, et al
   Tranilast Inhibits TGF-beta1-induced Epithelial-mesenchymal Transition and Invasion/Metastasis via the Suppression of Smad4 in Human Lung Cancer Cell Lines.
   Anticancer Res. 2020;40:3287-3296.
   PubMed         Abstract available
   
   
5. MOON SM, Kim JH, Kim SK, Kim S, et al
   Clinical Utility of Combined Circulating Tumor Cell and Circulating Tumor DNA Assays for Diagnosis of Primary Lung Cancer.
   Anticancer Res. 2020;40:3435-3444.
   PubMed         Abstract available
   
   
6. BAXA J, Ludvik J, Sedlmair M, Flohr T, et al
   Correlation of Iodine Quantification and FDG Uptake in Early Therapy Response Assessment of Non-small Cell Lung Cancer: Possible Benefit of Dual-energy CT Scan as an Integral Part of PET/CT Examination.
   Anticancer Res. 2020;40:3459-3468.
   PubMed         Abstract available
   
   
7. ABE T, Kobayashi N, Aoshika T, Ryuno Y, et al
   Pattern of Local Failure and its Risk Factors of Locally Advanced Non-small Cell Lung Cancer Treated With Concurrent Chemo-radiotherapy.
   Anticancer Res. 2020;40:3513-3517.
   PubMed         Abstract available
   
   
8. AOKI M, Ueda K, Umehara T, Kamimura GO, et al
   Targeted Therapy Followed by Cytotoxic Chemotherapy in Preoperative Patients With Locally Advanced Lung Adenocarcinoma.
   Anticancer Res. 2020;40:2911-2916.
   PubMed         Abstract available
   
   
9. KIM B, Kim SW, Lim JY, Park SJ, et al
   NCAPH Is Required for Proliferation, Migration and Invasion of Non-small-cell Lung Cancer Cells.
   Anticancer Res. 2020;40:3239-3246.
   PubMed         Abstract available
   
   

   
   BMC Cancer

10. CHEN J, Xia J, Huang J, Xu R, et al
    Effect of aspirin on PET parameters in primary non-small cell lung cancer and its relationship with prognosis.
    BMC Cancer. 2020;20:510.
    PubMed         Abstract available
    
    

    
    Cancer Cell

11. IRELAND AS, Micinski AM, Kastner DW, Guo B, et al
    MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate.
    Cancer Cell. 2020 May 30. pii: S1535-6108(20)30218.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

12. ZHAO YC, Tang D, Yang S, Liu H, et al
    Novel variants of ELP2 and PIAS1 in the interferon gamma signaling pathway are associated with non-small cell lung cancer survival.
    Cancer Epidemiol Biomarkers Prev. 2020 Jun 3. pii: 1055-9965.EPI-19-1450.
    PubMed         Abstract available
    
    

    
    Cancer Sci

13. WU ZX, Yang Y, Wang G, Wang JQ, et al
    Dual TTK/CLK2 inhibitor, CC-671, selectively antagonizes ABCG2-mediated multidrug resistance in lung cancer cells.
    Cancer Sci. 2020 Jun 1. doi: 10.1111/cas.14505.
    PubMed         Abstract available
    
    
14. SUN N, Sun S, Gao Y, Li Y, et al
    Utility of isocitrate dehydrogenase 1 as a serum protein biomarker for the early detection of non-small-cell lung cancer: A multicenter in vitro diagnostic clinical trial.
    Cancer Sci. 2020;111:1739-1749.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

15. VAN DEN BROECK A, Brambilla E, Moro-Sibilot D, Lantuejoul S, et al
    Correction: Editor's Note: Loss of Histone H4K20 Trimethylation Occurs in Preneoplasia and Influences Prognosis of Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2020;26:2767.
    PubMed        
    
    
16. VAN DEN BROECK A, Brambilla E, Moro-Sibilot D, Lantuejoul S, et al
    Correction: Loss of Histone H4K20 Trimethylation Occurs in Preneoplasia and Influences Prognosis of Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2020;26:2768.
    PubMed        
    
    

    
    Clin Lung Cancer

17. KAMIGAICHI A, Tsutani Y, Kagimoto A, Fujiwara M, et al
    Comparing Segmentectomy and Lobectomy for Clinical Stage IA Solid-dominant Lung Cancer Measuring 2.1 to 3 cm.
    Clin Lung Cancer. 2020 May 7. pii: S1525-7304(20)30138.
    PubMed         Abstract available
    
    

    
    Eur Respir J

18. KIM YW, Kang HR, Kwon BS, Lim SY, et al
    Low-dose chest computed tomographic screening and invasive diagnosis of pulmonary nodules for lung cancer in never-smokers.
    Eur Respir J. 2020 Jun 1. pii: 13993003.00177-2020.
    PubMed         Abstract available
    
    

    
    Int J Cancer

19. HOPKINS AM, Wagner J, Kichenadasse G, Modi N, et al
    Patient-reported outcomes as a prognostic marker of survival in patients with advanced non-small cell lung cancer treated with immunotherapy: PROs as a prognostic marker for immunotherapies.
    Int J Cancer. 2020 Jun 3. doi: 10.1002/ijc.33133.
    PubMed         Abstract available
    
    
20. HOU HH, Pan HJ, Liao WY, Lee CH, et al
    Autophagy in fibroblasts induced by cigarette smoke extract promotes invasion in lung cancer cells.
    Int J Cancer. 2020 Jun 3. doi: 10.1002/ijc.33127.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

21. PAUL S, Bodner WR, Garg M, Tang J, et al
    Cardiac Irradiation Predicts Activity Decline in Patients Receiving Concurrent Chemoradiation for Locally Advanced Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2020 Jun 1. pii: S0360-3016(20)31208.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

22. LUO G, Tang M, Zhao Q, Lu L, et al
    Bone marrow adipocytes enhance osteolytic bone destruction by activating 1q21.3(S100A7/8/9-IL6R)-TLR4 pathway in lung cancer.
    J Cancer Res Clin Oncol. 2020 Jun 3. pii: 10.1007/s00432-020-03277.
    PubMed         Abstract available
    
    
23. HUI Z, Wei F, Ren H, Xu W, et al
    Primary tumor standardized uptake value (SUVmax) measured on (18)F-FDG PET/CT and mixed NSCLC components predict survival in surgical-resected combined small-cell lung cancer.
    J Cancer Res Clin Oncol. 2020 Jun 3. pii: 10.1007/s00432-020-03240.
    PubMed         Abstract available
    
    
24. AARNINK A, Fumet JD, Favier L, Truntzer C, et al
    Role of pleural and peritoneal metastasis in immune checkpoint inhibitors efficacy patients with non-small cell lung cancer: real-world data from a large cohort in France.
    J Cancer Res Clin Oncol. 2020 May 30. pii: 10.1007/s00432-020-03262.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

25. CHEN D, Wu X, Wen J, Xue Y, et al
    Comparison of sublobar resection and lobectomy for patients with small (
    J Surg Oncol. 2020 Jun 1. doi: 10.1002/jso.26051.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

26. WANG F, Adjei AA
    Does the Lung Cancer Field Need Another Third-Generation EGFR Tyrosine Kinase Inhibitor?
    J Thorac Oncol. 2020;15:881-883.
    PubMed        
    
    
27. RUIZ R, Galvez-Nino M, Poquioma E, Limache-Garcia A, et al
    Lung Cancer in Peru.
    J Thorac Oncol. 2020;15:891-898.
    PubMed        
    
    
28. OUYANG W, Hu J, Zhang H, Xie C, et al
    The Management of Patients With Lung Cancer During the Outbreak of Coronavirus Disease 2019.
    J Thorac Oncol. 2020 May 23. pii: S1556-0864(20)30385.
    PubMed        
    
    

    
    JAMA Oncol

29. BERCHUCK JE, Meyer CS, Zhang N, Berchuck CM, et al
    Association of Mental Health Treatment With Outcomes for US Veterans Diagnosed With Non-Small Cell Lung Cancer.
    JAMA Oncol. 2020 Jun 4. pii: 2766567. doi: 10.1001/jamaoncol.2020.1466.
    PubMed         Abstract available
    
    
30. RUSTHOVEN CG, Yamamoto M, Bernhardt D, Smith DE, et al
    Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases: The FIRE-SCLC Cohort Study.
    JAMA Oncol. 2020 Jun 4. pii: 2766565. doi: 10.1001/jamaoncol.2020.1271.
    PubMed         Abstract available
    
    
31. LE PECHOUX C, Levy A
    Radiosurgery in Patients With Small Cell Lung Cancer With Brain Metastases: A Call for Prospective Evidence.
    JAMA Oncol. 2020 Jun 4. pii: 2766562. doi: 10.1001/jamaoncol.2020.1245.
    PubMed        
    
    

    
    Lancet Gastroenterol Hepatol

32. WINTHER SB, Liposits G, Skuladottir H, Hofsli E, et al
    Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial.
    Lancet Gastroenterol Hepatol. 2019 Mar 6. pii: S2468-1253(19)30041.
    PubMed         Abstract available
    
    

    
    Lancet Respir Med

33. ROSELL R, Chaib I, Santarpia M
    Targeting MET amplification in EGFR-mutant non-small-cell lung cancer.
    Lancet Respir Med. 2020 May 29. pii: S2213-2600(20)30171.
    PubMed        
    
    
34. WU YL, Cheng Y, Zhou J, Lu S, et al
    Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
    Lancet Respir Med. 2020 May 29. pii: S2213-2600(20)30154.
    PubMed         Abstract available
    
    

    
    Lung Cancer

35. FRUH M, Panje CM, Reck M, Blackhall F, et al
    Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts.
    Lung Cancer. 2020;146:6-11.
    PubMed         Abstract available
    
    
36. ROSSI G, Caruso D, Nosseir S, Banchelli I, et al
    A modern approach to advanced Non-Small Cell Lung Cancer: minimally-invasive procedures and in parallel multiple DNA/RNA high-throughput sequencing.
    Lung Cancer. 2020 May 14. pii: S0169-5002(20)30430.
    PubMed        
    
    

    
    N Engl J Med

37. ARMSTRONG KA, Cohen JV, Shepard JO, Folch EE, et al
    Case 16-2020: A 47-Year-Old Woman with Recurrent Melanoma and Pulmonary Nodules.
    N Engl J Med. 2020;382:2034-2043.
    PubMed        
    
    

    
    Nat Med

38. JOSHI K, de Massy MR, Ismail M, Reading JL, et al
    Publisher Correction: Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer.
    Nat Med. 2020 Jun 3. pii: 10.1038/s41591-020-0866.
    PubMed         Abstract available
    
    
39. BISWAS D, Birkbak NJ, Rosenthal R, Hiley CT, et al
    Publisher Correction: A clonal expression biomarker associates with lung cancer mortality.
    Nat Med. 2020 Jun 3. pii: 10.1038/s41591-020-0899.
    PubMed         Abstract available
    
    

    
    Oncol Rep

40. MIERZEJEWSKA J, Szczygiel A, Anger-Gora N, Rossowska J, et al
    DeOacylated lipooligosaccharide of E. coli B reduces the number of metastatic foci via downregulation of myeloid cell activity.
    Oncol Rep. 2020;43:270-281.
    PubMed         Abstract available
    
    

    
    Oncologist

41. JAHANZEB M, Lin HM, Pan X, Yin Y, et al
    Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung Cancer.
    Oncologist. 2020 Jun 3. doi: 10.1634/theoncologist.2020-0011.
    PubMed         Abstract available
    
    

    
    PLoS One

42. CHEN R, Lin J
    Identification of feature risk pathways of smoking-induced lung cancer based on SVM.
    PLoS One. 2020;15:e0233445.
    PubMed         Abstract available
    
    
43. YOON HY, Ryu JS, Sim YS, Kim D, et al
    Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study.
    PLoS One. 2020;15:e0228925.
    PubMed         Abstract available
    
    
44. ALLEN KL, Cann J, Zhao W, Peterson N, et al
    Upregulation of annexin A1 protein expression in the intratumoral vasculature of human non-small-cell lung carcinoma and rodent tumor models.
    PLoS One. 2020;15:e0234268.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: